Hipertension y Riesgo Vascular最新文献_第6页

Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure 坎地沙坦与缬沙坦联合氨氯地平对外周和中枢血压的安全性和有效性比较

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.11.004

S.M. Hanna , H.M. Rabea , M.E.A. Abdelrahim , H.B. Mahmoud

{"title":"Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure","authors":"S.M. Hanna , H.M. Rabea , M.E.A. Abdelrahim , H.B. Mahmoud","doi":"10.1016/j.hipert.2023.11.004","DOIUrl":"10.1016/j.hipert.2023.11.004","url":null,"abstract":"<div><h3>Introduction</h3><p>“Amlodipine/valsartan” or “amlodipine/candesartan” combinations represent two effective antihypertensive agents with complementary mechanisms of action. Nevertheless, a study has yet to be done to evaluate the effect of amlodipine/candesartan on central blood pressure and compare it with amlodipine/valsartan combination. To see how “amlodipine plus candesartan combination” reduces peripheral and central blood pressure compared to the most studied combination, “amlodipine plus valsartan”.</p></div><div><h3>Material and methods</h3><p>Eighty-six patients were randomized in an open-label, prospective study by 1:1 ratio to two groups. Group I (<em>n</em>  =44) received the amlodipine and candesartan combination. Peripheral and central blood pressure (CBP) was measured at baseline, at 6 and 12 weeks of follow-up.</p></div><div><h3>Discussion</h3><p>Both treatment groups reduced peripheral systolic, diastolic, and mean blood pressure. There was no significant difference between and within both groups. The amlodipine/candesartan combination showed more reduction in peripheral systolic blood pressure (PSBP) after 12 weeks of treatment (<em>p</em>  =<0.001). The two treatment groups did not exert significant efficacy in lowering heart rate (HR) and augmentation index% (AIx%).</p></div><div><h3>Conclusion</h3><p>To conclude, the amlodipine 10mg/candesartan 16mg combination was non-inferior to the amlodipine 10mg/valsartan 160mg combination in terms of reducing peripheral and CBP over time.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 17-25"},"PeriodicalIF":0.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efecto del alcohol sobre la presión arterial 酒精对血压的影响

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2024.02.003

引用次数: 0

Comment on the update of the 2023 European Society of Hypertension (ESH) guidelines for the management of arterial hypertension 对 2023 年欧洲高血压学会（ESH）动脉高血压管理指南的更新发表评论。

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2024.02.004

E. Rodilla , M. Gorostidi

引用次数: 0

La dieta mediterránea incluso en hiperpotasemia y enfermedad renal crónica [地中海饮食，即使在高钾血症和慢性肾病中也是如此]。

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.11.003

M.A. Maria Tablado

引用次数: 0

Cefalea e hipertensión como forma de presentación de un feocromocitoma y simulando un síndrome post-COVID-19 [头痛和高血压是嗜铬细胞瘤的一种表现形式，类似于 COVID-19 后综合征]。

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.09.002

M.P. Pérez García , J.F. García Granado , F.J. Martínez Martín

引用次数: 0

Mortality and cardiovascular risk in vasculitis ANCA. Importance of hypertension and renal function. Experience from southern Spain 血管炎 ANCA 的死亡率和心血管风险。高血压和肾功能的重要性。西班牙南部的经验。

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.06.001

M.A. Martin-Gómez , A. Rodríguez Torres , M. Espinosa Hernández , M. Lopez Mendoza , J.M. Sabio Sánchez , M. Martin Armada , I. Martin Suarez , J.L. Callejas Rubio , M.M. Castilla Castellano , J.C. Anglada Pintado , A.C. Barnosi Marín , M.D. Martinez Esteban , L. Castilla Guerra , E. De Ramón Garrido , on behalf of the Andalusian Association of Autoimmune Diseases (AADEA) and the Andalusian Society of Arterial Hypertension (SAHTA)

{"title":"Mortality and cardiovascular risk in vasculitis ANCA. Importance of hypertension and renal function. Experience from southern Spain","authors":"M.A. Martin-Gómez , A. Rodríguez Torres , M. Espinosa Hernández , M. Lopez Mendoza , J.M. Sabio Sánchez , M. Martin Armada , I. Martin Suarez , J.L. Callejas Rubio , M.M. Castilla Castellano , J.C. Anglada Pintado , A.C. Barnosi Marín , M.D. Martinez Esteban , L. Castilla Guerra , E. De Ramón Garrido , on behalf of the Andalusian Association of Autoimmune Diseases (AADEA) and the Andalusian Society of Arterial Hypertension (SAHTA)","doi":"10.1016/j.hipert.2023.06.001","DOIUrl":"10.1016/j.hipert.2023.06.001","url":null,"abstract":"<div><h3>Background</h3><p>Cardiovascular disease (CVD) is one of the principal causes of death in antineutrophil cytoplasmic antibody-(ANCA)-associated vasculitis (AAV).</p></div><div><h3>Objectives</h3><p>To evaluate the mortality and it's causes and CVD and its vascular risk factors (VRFs) in AAV patients in Andalusia.</p></div><div><h3>Methods</h3><p>A multicenter cohort of 220 AAV patients followed-up from 1979 until June 2020 was studied in Andalussia, south of Spain. The information, including socio-demographic and clinical data was recorded retrospectively through chart review. Data was analysed using Chi<sup>2</sup>, ANOVA and Cox proportional hazards regresion as uni and multivariate test with a 95% confidence interval (CI).</p></div><div><h3>Results</h3><p>During a mean ± standard deviation follow-up of 96.79 ± 75.83 months, 51 patients died and 30 presented at least one CVE. Independent prognostic factors of mortality were age (HR 1.083, p=0.001) and baseline creatinine (HR 4.41, p=0.01). Independent prognostic factors of CVE were age [hazard ratio (HR) 1.042, p=0.005] and the presence of hypertension (HTN) six months after diagnosis (HR 4.641, p=0.01). HTN, diabetes and renal failure, all of these important VRFs, are more prevalent in AAV patients than it is described in matched general population.</p></div><div><h3>Conclusions</h3><p>Age and baseline renal function, but not CVEs, are predictors of mortality and age and early HTN are independent predictors for having a CVE. CVD screening in AAV patients is demanded.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 5-16"},"PeriodicalIF":0.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10255089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence on the use of alternative substances and therapies in hypertension 使用替代物质和疗法治疗高血压的证据。

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.11.001

E. Martín-Riobóo , M. Turégano-Yedro , J.R. Banegas

{"title":"Evidence on the use of alternative substances and therapies in hypertension","authors":"E. Martín-Riobóo , M. Turégano-Yedro , J.R. Banegas","doi":"10.1016/j.hipert.2023.11.001","DOIUrl":"10.1016/j.hipert.2023.11.001","url":null,"abstract":"<div><h3>Objective</h3><p>Review of some of the best-known biological and non-biological complementary/alternative therapies/medicines (CAM) and their relationship with blood pressure (BP) and hypertension (HT).</p></div><div><h3>Search strategy</h3><p><span>Narrative review assessing a recent series of systematic reviews, meta-analyses, and </span>clinical trials published in recent years, focusing on the effects of CAM on BP and HT.</p></div><div><h3>Selection of studies</h3><p>We searched EMBASE, MEDLINE, Cochrane Library and Google Scholar, obtaining a total of 4336 articles, finally limiting the search to 181 after applying filters.</p></div><div><h3>Synthesis of results</h3><p><span>Some studies on biological therapies show some usefulness in </span>BP reduction with an adequate benefit–risk balance, although there is a scarcity of high-quality trials that support these results. Some mind-body therapies have shown hypothetical benefit; in contrast, others lack robust evidence.</p></div><div><h3>Conclusions</h3><p>Although some therapies present a reasonable risk–benefit ratio, they should in no case replace pharmacological treatment when indicated.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 40-57"},"PeriodicalIF":0.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic performance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for mortality in patients with acute stroke 中性粒细胞/淋巴细胞比率和血小板/淋巴细胞比率对急性脑卒中患者死亡率的预后作用。

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.10.002

R.F. Cáceda-Samamé , M.R. Vela-Salazar , R. Alejandro-Salinas , A.P. Llamo-Vilcherrez , C.J. Toro-Huamanchumo

{"title":"Prognostic performance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for mortality in patients with acute stroke","authors":"R.F. Cáceda-Samamé , M.R. Vela-Salazar , R. Alejandro-Salinas , A.P. Llamo-Vilcherrez , C.J. Toro-Huamanchumo","doi":"10.1016/j.hipert.2023.10.002","DOIUrl":"10.1016/j.hipert.2023.10.002","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the prognostic performance of the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) for mortality in patients with acute stroke treated at a Peruvian hospital.</p></div><div><h3>Design</h3><p>Retrospective cohort study.</p></div><div><h3>Setting</h3><p>Tertiary care hospital.</p></div><div><h3>Patients</h3><p>Patients aged ≥18 years with a diagnosis of acute stroke and admitted to the hospital from May 2019 to June 2021.</p></div><div><h3>Interventions</h3><p>None.</p></div><div><h3>Main variables of interests</h3><p>Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mortality.</p></div><div><h3>Results</h3><p>A total of 165 patients were included. The mean age was 66.1±14.2 years, and 59.4% were male. Only NLR had a performance superior to 0.7 (AUC: 0.75; 95%CI: 0.65–0.85), and its elevated levels were associated with an increased risk of mortality (aRR: 3.66; 95%CI: 1.77–8.85) after adjusting for confounders.</p></div><div><h3>Conclusion</h3><p>The neutrophil-to-lymphocyte ratio has an acceptable prognostic performance for mortality in patients with acute stroke. Its use may be considered to stratify patients’ risk and to consider timely alternative care and management.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 26-34"},"PeriodicalIF":0.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139940869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

La música como tratamiento de la hipertensión 音乐治疗高血压

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2024.02.002

引用次数: 0

Hypertensive emergency secondary to atropine 继发于阿托品的高血压急症。

IF 0.6

Hipertension y Riesgo Vascular Pub Date : 2024-01-01 DOI: 10.1016/j.hipert.2023.08.003

P.R. Carvalho, F. Gonçalves, P. Magalhães, J.I. Moreira

{"title":"Hypertensive emergency secondary to atropine","authors":"P.R. Carvalho, F. Gonçalves, P. Magalhães, J.I. Moreira","doi":"10.1016/j.hipert.2023.08.003","DOIUrl":"10.1016/j.hipert.2023.08.003","url":null,"abstract":"<div><p>Atropine, a competitive antagonist of acetylcholine muscarinic receptors, is commonly used to treat severe bradycardia by blocking parasympathetic activity. We present a rare case of hypertensive emergency following atropine administration, with only one previous report in the literature.</p><p>A 78-year-old woman with essential hypertension and hypercholesterolemia was admitted to the cardiac intensive care unit for non-ST segment elevation myocardial infarction. During coronary angiography, an occlusion of the right coronary artery was identified. While removing the diagnostic catheter through the right radial artery, the patient experienced intense pain and discomfort, accompanied by a vasovagal reflex characterized by bradycardia and hypotension. Intravenous atropine (0.5mg) was administered, leading to a rapid rise in heart rate with frequent ventricular ectopy. Subsequently, a progressive and exaggerated elevation in arterial blood pressure occurred, peaking at 294/121mmHg approximately 10min after atropine administration. The patient developed hypertensive acute pulmonary edema, successfully treated with intravenous nitroglycerine (10mg) and furosemide (60mg). Blood pressure normalized after approximately 14min.</p><p>The exact mechanism of atropine-induced hypertensive emergency remains unknown. While hypertensive emergencies with atropine are exceedingly rare, healthcare professionals should be aware of this potential effect and be prepared for prompt intervention.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 58-61"},"PeriodicalIF":0.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139973936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0